Zevaskyn is the first and only autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa ...

The FDA has approved Zevaskyn for the treatment of recessive dystrophic epidermolysis bullosa, the company announced in a ...

The U.S. Food and Drug Administration has approved Zevaskyn for patients suffering from rare, genetic skin disease recessive ...

ABEO READ THE FULL ABEO RESEARCH REPORT Business Update Zevaskyn™ Approved by FDA On April 29, 2025, Abeona Therapeutics, Inc. (NASDAQ:ABEO) announced that the U.S. Food and Drug Administration (FDA) ...

The US Food and Drug Administration (FDA) has approved Abeona Therapeutics’ Zevaskyn (prademagene zamikeracel) for use in ...

In a significant advancement for the Recessive Dystrophic Epidermolysis Bullosa (RDEB) community, the U.S. Food and Drug ...

The US Food and Drug Administration (FDA) has approved Zevaskyn (prademagene zamikeracel) gene-modified cellular sheets, also ...

Patients with the debilitating dermatologic condition are born with COL7A1 mutations in both gene copies, affecting the ...

Zevaskyn, which Abeona priced at $3.1 million, treats epidermolysis bullosa. It will compete with a gene therapy from Krystal ...

Persistence has paid off for Abeona Therapeutics and its gene therapy for recessive dystrophic epidermolysis bullosa (RDEB).